J Drug Target. 2024 May 14. 1-21
Nanoparticles (NPs) have played a pivotal role in various biomedical applications, spanning from sensing to drug delivery, imaging, and antiviral therapy. The therapeutic utilization of NPs in clinical trials was established in the early 1990s. Silver nanoparticles (AgNPs) possess antimicrobial, anticancer, and antiviral properties, which make them a possible antiviral drug to combat the COVID-19 virus. Free radicals and reactive oxygen species (ROS) are produced by AgNPs, which causes apoptosis induction and prevents viral contamination. The shape and size of AgNPs can influence their interactions and biological activities. Therefore, it is recommended that silver nanoparticles (AgNPs) be used as a valuable tool in the management of COVID-19 pandemic. These nanoparticles possess strong antimicrobial properties, allowing them to penetrate and destroy microbial cells. Additionally, the toxicity level of nanoparticles depends on the administered dose, and surface modifications are necessary to reduce toxicity, preventing direct interaction between metal surfaces and cells. By utilizing silver nanoparticles, drugs can be targeted to specific areas in the body. For example, in the case of COVID-19, antiviral drugs can be stimulated as nanoparticles in the lungs to accelerate disease recovery. Nanoparticle-based systems have the capability to transport drugs and treat specific body parts. This review offers an examination of silver nanoparticle-based drug delivery systems for combatting COVID-19, with the objective of boosting the bioavailability of existing medications, decreasing their toxicity and raising their efficiency.
Keywords: SARS-CoV-2; Silver nanoparticles; bioavailability; drug delivery systems; toxicity